Clinical Trial Update: Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 2 trial evaluating statin monotherapy for endocrine metabolic disease risk in individuals with spinal cord injury…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Osteoporosis
• Spinal Cord Injury

Drugs mentioned

• Statin (statin)

Snippet

Sponsor: Dr. B. Catharine. Craven | Conditions: Spinal Cord Injuries, Osteoporosis | Phase 2 | Status: TERMINATED